{
  "consolidation_metadata": {
    "timestamp": "2025-10-01T17:20:13.709584",
    "indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
    "consolidation_type": "picos",
    "data_split": "test",
    "total_consolidated_picos": 82,
    "source_countries": [
      "AT",
      "BE",
      "DE",
      "DK",
      "EN",
      "ES",
      "EU",
      "FR",
      "IT",
      "NL",
      "PO",
      "PT",
      "SE"
    ],
    "source_types": [
      "clinical_guideline",
      "hta_submission"
    ]
  },
  "consolidated_picos": [
    {
      "Population": "adults with HCC in Barcelona Clinic Liver Cancer (BCLC) stage B or C who did not receive any prior systemic therapy for the advanced or inoperable disease. Hepatic cirrhosis of any aetiology was not an exclusion criterion. Patients in BCLC stage B had to be ineligible for transarterial chemoembolization (TACE). Further inclusion criteria were Child-Pugh stage A and an Eastern Cooperative Oncology Group – Performance Status (ECOG-PS) score of 0 or 1.",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "adults with HCC in Barcelona Clinic Liver Cancer (BCLC) stage B or C who did not receive any prior systemic therapy for the advanced or inoperable disease. Hepatic cirrhosis of any aetiology was not an exclusion criterion. Patients in BCLC stage B had to be ineligible for transarterial chemoembolization (TACE). Further inclusion criteria were Child-Pugh stage A and an Eastern Cooperative Oncology Group – Performance Status (ECOG-PS) score of 0 or 1.",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "Adult patients with advanced or inoperable hepatocellular carcinoma (HCC) who have not yet received systemic therapy: with Child-Pugh A or no hepatic cirrhosis",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "Adult patients with advanced or inoperable hepatocellular carcinoma (HCC) who have not yet received systemic therapy: with Child-Pugh A or no hepatic cirrhosis",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "Adult patients with advanced or inoperable hepatocellular carcinoma (HCC) who have not yet received systemic therapy: with Child-Pugh B",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "BSC",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "Adult patients with advanced or inoperable hepatocellular carcinoma (HCC) who have not yet received systemic therapy: with Child-Pugh B",
        "intervention": "Medicine X (under assessment)",
        "comparator": "BSC"
      }
    },
    {
      "Population": "Child-Pugh A patients with unresectable HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "placebo",
      "Countries": [
        "AT",
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 2,
      "Grouping_Key": {
        "population": "Child-Pugh A patients with unresectable HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "placebo"
      }
    },
    {
      "Population": "adult patients with advanced (unresectable or metastatic) HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "placebo or placebo-based (without sorafenib) therapy",
      "Countries": [
        "AT",
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 2,
      "Grouping_Key": {
        "population": "adult patients with advanced (unresectable or metastatic) HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "placebo or placebo-based (without sorafenib) therapy"
      }
    },
    {
      "Population": "hepatocellular carcinoma patients",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "Placebo",
      "Countries": [
        "AT",
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 2,
      "Grouping_Key": {
        "population": "hepatocellular carcinoma patients",
        "intervention": "Medicine X (under assessment)",
        "comparator": "Placebo"
      }
    },
    {
      "Population": "Adult patients with advanced or inoperable hepatocellular carcinoma (HCC) who have not yet received systemic therapy:  with Child-Pugh A or no hepatic cirrhosis",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "Sorafenib",
      "Countries": [
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "Adult patients with advanced or inoperable hepatocellular carcinoma (HCC) who have not yet received systemic therapy:  with Child-Pugh A or no hepatic cirrhosis",
        "intervention": "Medicine X (under assessment)",
        "comparator": "Sorafenib"
      }
    },
    {
      "Population": "Adult patients with advanced or inoperable hepatocellular carcinoma (HCC) who have not yet received systemic therapy:  with Child-Pugh B",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "BSC",
      "Countries": [
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "Adult patients with advanced or inoperable hepatocellular carcinoma (HCC) who have not yet received systemic therapy:  with Child-Pugh B",
        "intervention": "Medicine X (under assessment)",
        "comparator": "BSC"
      }
    },
    {
      "Population": "Adult patients with advanced HCC and adult patients with inoperable HCC not previously treated systemically.",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib (Nexavar)",
      "Countries": [
        "DK"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "Adult patients with advanced HCC and adult patients with inoperable HCC not previously treated systemically.",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib (Nexavar)"
      }
    },
    {
      "Population": "adults with advanced or unresectable hepatocellular carcinoma (HCC) who have not had previous systemic treatment, only if they have Child-Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "EN"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "adults with advanced or unresectable hepatocellular carcinoma (HCC) who have not had previous systemic treatment, only if they have Child-Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "adults with advanced or unresectable hepatocellular carcinoma (HCC) who have not had previous systemic treatment, only if they have Child-Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "lenvatinib",
      "Countries": [
        "EN"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "adults with advanced or unresectable hepatocellular carcinoma (HCC) who have not had previous systemic treatment, only if they have Child-Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
        "intervention": "Medicine X (under assessment)",
        "comparator": "lenvatinib"
      }
    },
    {
      "Population": "patients aged 18 years or older and diagnosed with locally advanced or metastatic and/ or unresectable HCC with histological/ cytological confirmation or clinical features consistent with the American Association for the Study of the Liver (AASLD) criteria in cirrhotic patients",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "ES"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients aged 18 years or older and diagnosed with locally advanced or metastatic and/ or unresectable HCC with histological/ cytological confirmation or clinical features consistent with the American Association for the Study of the Liver (AASLD) criteria in cirrhotic patients",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "patients with advanced and/ or unresectable hepatocellular carcinoma who have not received prior systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "ES"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced and/ or unresectable hepatocellular carcinoma who have not received prior systemic therapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "lenvatinib",
      "Countries": [
        "ES"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "lenvatinib"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "placebo",
      "Countries": [
        "ES"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "placebo"
      }
    },
    {
      "Population": "adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma (stage BCLC B or C) who have not received prior systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma (stage BCLC B or C) who have not received prior systemic therapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma with preserved general condition (ECOG ≤ 2) and preserved hepatic function (Child-Pugh A) who have not received prior systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma with preserved general condition (ECOG ≤ 2) and preserved hepatic function (Child-Pugh A) who have not received prior systemic therapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "patients classified as Stage B (not eligible for chemoembolism) or C by the BCLC (Barcelona Clinic Liver Cancer) classification, Child-Pugh score A, ECOG score of 0 to 1, who have not received prior systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients classified as Stage B (not eligible for chemoembolism) or C by the BCLC (Barcelona Clinic Liver Cancer) classification, Child-Pugh score A, ECOG score of 0 to 1, who have not received prior systemic therapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "patients with advanced hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "placebo",
      "Countries": [
        "NL"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "placebo"
      }
    },
    {
      "Population": "patients with hepatocellular carcinoma for whom initiation of curative treatment or (continuation of) locoregional or local palliative treatment is not possible or considered medically inappropriate (hepatocell carcinomas)",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "best care regimen available",
      "Countries": [
        "NL"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with hepatocellular carcinoma for whom initiation of curative treatment or (continuation of) locoregional or local palliative treatment is not possible or considered medically inappropriate (hepatocell carcinomas)",
        "intervention": "Medicine X (under assessment)",
        "comparator": "best care regimen available"
      }
    },
    {
      "Population": "patients with unresectable HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "PT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with unresectable HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "adult patients with advanced or non-resectable hepatocellular carcinoma (HCC) and who have not received any previous systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "PT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "adult patients with advanced or non-resectable hepatocellular carcinoma (HCC) and who have not received any previous systemic therapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "first-line treatment of adult patients with advanced or non-resectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "atezolizumab plus bevacizumab",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "first-line treatment of adult patients with advanced or non-resectable hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "atezolizumab plus bevacizumab"
      }
    },
    {
      "Population": "first-line treatment of adult patients with advanced or non-resectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "first-line treatment of adult patients with advanced or non-resectable hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "first-line treatment of adult patients with advanced or non-resectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "lenvatinib",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "first-line treatment of adult patients with advanced or non-resectable hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "lenvatinib"
      }
    },
    {
      "Population": "patients whose HCC has non-viral etiology",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "atezolizumab plus bevacizumab",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients whose HCC has non-viral etiology",
        "intervention": "Medicine X (under assessment)",
        "comparator": "atezolizumab plus bevacizumab"
      }
    },
    {
      "Population": "HCCP patients with Child-Pugh stage A and BC or BLC, with remote tumor measurements or localization that cannot be re-regionised or resected",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "atezolizumab and bevacizumab",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "HCCP patients with Child-Pugh stage A and BC or BLC, with remote tumor measurements or localization that cannot be re-regionised or resected",
        "intervention": "Medicine X (under assessment)",
        "comparator": "atezolizumab and bevacizumab"
      }
    },
    {
      "Population": "HCCP patients with Child-Pugh stage A and BC or BLC, with remote tumor measurements or localization that cannot be re-regionised or resected",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "durumavalumab plus tremelimumab",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "HCCP patients with Child-Pugh stage A and BC or BLC, with remote tumor measurements or localization that cannot be re-regionised or resected",
        "intervention": "Medicine X (under assessment)",
        "comparator": "durumavalumab plus tremelimumab"
      }
    },
    {
      "Population": "Patients with contraindications for A+B and D+T",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "one of the two tyrosine kinase biliary carcinomas",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "Patients with contraindications for A+B and D+T",
        "intervention": "Medicine X (under assessment)",
        "comparator": "one of the two tyrosine kinase biliary carcinomas"
      }
    },
    {
      "Population": "individual Child Pugh Stage B HCC patients (up to 8 points), with long-term metastasis or tumour localization that is not locally monitored or resectable, and an ECOG status of 0 - 1",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "immunotherapy with an anti-PD-1 antibody",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "individual Child Pugh Stage B HCC patients (up to 8 points), with long-term metastasis or tumour localization that is not locally monitored or resectable, and an ECOG status of 0 - 1",
        "intervention": "Medicine X (under assessment)",
        "comparator": "immunotherapy with an anti-PD-1 antibody"
      }
    },
    {
      "Population": "patients with unresectable HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "arterial chemoembolization",
      "Countries": [
        "BE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with unresectable HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "arterial chemoembolization"
      }
    },
    {
      "Population": "patients with unresectable HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "radioactive Iodine 131 treatment",
      "Countries": [
        "BE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with unresectable HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "radioactive Iodine 131 treatment"
      }
    },
    {
      "Population": "patients with unresectable HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "systemic chemotherapy (doxorubicin or cisplatin)",
      "Countries": [
        "BE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with unresectable HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "systemic chemotherapy (doxorubicin or cisplatin)"
      }
    },
    {
      "Population": "patients with unresectable HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "hormonal therapy with tamoxifen",
      "Countries": [
        "BE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with unresectable HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "hormonal therapy with tamoxifen"
      }
    },
    {
      "Population": "patients with unresectable HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "octreotide",
      "Countries": [
        "BE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with unresectable HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "octreotide"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "conventional TACE",
      "Countries": [
        "DE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "conventional TACE"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "drug-eluting bead TACE",
      "Countries": [
        "DE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "drug-eluting bead TACE"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "transarterial radio-embolization (TARE)",
      "Countries": [
        "DE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "transarterial radio-embolization (TARE)"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "best supportive care",
      "Countries": [
        "DE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "best supportive care"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma with preserved hepatic function and in good general condition where resection, transplantation, ablation or TACE/SIRT cannot be performed or are not expected to have an effect, or for patients with additional hepatic disease",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "atezolizumab and bevacizumab",
      "Countries": [
        "DK"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma with preserved hepatic function and in good general condition where resection, transplantation, ablation or TACE/SIRT cannot be performed or are not expected to have an effect, or for patients with additional hepatic disease",
        "intervention": "Medicine X (under assessment)",
        "comparator": "atezolizumab and bevacizumab"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma with preserved hepatic function and in good general condition where resection, transplantation, ablation or TACE/SIRT cannot be performed or are not expected to have an effect, or for patients with additional hepatic disease",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "DK"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma with preserved hepatic function and in good general condition where resection, transplantation, ablation or TACE/SIRT cannot be performed or are not expected to have an effect, or for patients with additional hepatic disease",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma with preserved hepatic function and in good general condition where resection, transplantation, ablation or TACE/SIRT cannot be performed or are not expected to have an effect, or for patients with additional hepatic disease",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "lenvatinib",
      "Countries": [
        "DK"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma with preserved hepatic function and in good general condition where resection, transplantation, ablation or TACE/SIRT cannot be performed or are not expected to have an effect, or for patients with additional hepatic disease",
        "intervention": "Medicine X (under assessment)",
        "comparator": "lenvatinib"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma with preserved hepatic function who have tolerated and subsequently progressed to second-line therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "regorafenib",
      "Countries": [
        "DK"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma with preserved hepatic function who have tolerated and subsequently progressed to second-line therapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "regorafenib"
      }
    },
    {
      "Population": "advanced disease, systemic treatment should be offered to patients with ECOG/PS 0-1 and Child–Pugh class A",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "BSC",
      "Countries": [
        "ES"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "advanced disease, systemic treatment should be offered to patients with ECOG/PS 0-1 and Child–Pugh class A",
        "intervention": "Medicine X (under assessment)",
        "comparator": "BSC"
      }
    },
    {
      "Population": "patients with compensated cirrhosis (Child-Pugh score A), in good general condition (PS 0-2), and advanced HCC (BCLC C or B not eligible for TACE)",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with compensated cirrhosis (Child-Pugh score A), in good general condition (PS 0-2), and advanced HCC (BCLC C or B not eligible for TACE)",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "patients with compensated cirrhosis (Child-Pugh score A), in good general condition (PS 0-2), and advanced HCC (BCLC C or B not eligible for TACE)",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "lenvatinib",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with compensated cirrhosis (Child-Pugh score A), in good general condition (PS 0-2), and advanced HCC (BCLC C or B not eligible for TACE)",
        "intervention": "Medicine X (under assessment)",
        "comparator": "lenvatinib"
      }
    },
    {
      "Population": "patients with advanced HCC previously treated with sorafenib",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "regorafenib",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced HCC previously treated with sorafenib",
        "intervention": "Medicine X (under assessment)",
        "comparator": "regorafenib"
      }
    },
    {
      "Population": "patients with advanced HCC previously treated with sorafenib",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "cabozantinib",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced HCC previously treated with sorafenib",
        "intervention": "Medicine X (under assessment)",
        "comparator": "cabozantinib"
      }
    },
    {
      "Population": "patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (AFP > 400 ng/mL) after sorafenib",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "ramucirumab",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (AFP > 400 ng/mL) after sorafenib",
        "intervention": "Medicine X (under assessment)",
        "comparator": "ramucirumab"
      }
    },
    {
      "Population": "patients with advanced hepatocellular carcinoma previously treated with sorafenib",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "nivolumab plus ipilimumab",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced hepatocellular carcinoma previously treated with sorafenib",
        "intervention": "Medicine X (under assessment)",
        "comparator": "nivolumab plus ipilimumab"
      }
    },
    {
      "Population": "patients with advanced hepatocellular carcinoma with portal vein thrombosis, in good PS, Child-Pugh A and ineligible (or after failure) to sorafenib",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "SIRT with Therasphere",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced hepatocellular carcinoma with portal vein thrombosis, in good PS, Child-Pugh A and ineligible (or after failure) to sorafenib",
        "intervention": "Medicine X (under assessment)",
        "comparator": "SIRT with Therasphere"
      }
    },
    {
      "Population": "patients with advanced HCC who have failed or are not eligible for local-regional therapy, with impaired hepatic function (Child-Pugh B)",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "IT"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced HCC who have failed or are not eligible for local-regional therapy, with impaired hepatic function (Child-Pugh B)",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "patients with advanced HCC and Child-Pugh B liver cirrhosis",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "IT"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced HCC and Child-Pugh B liver cirrhosis",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "patients with advanced HCC and Child-Pugh C liver cirrhosis",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "best supportive therapy",
      "Countries": [
        "IT"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced HCC and Child-Pugh C liver cirrhosis",
        "intervention": "Medicine X (under assessment)",
        "comparator": "best supportive therapy"
      }
    },
    {
      "Population": "patients with advanced stage of HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "FOLFOX4",
      "Countries": [
        "IT"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced stage of HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "FOLFOX4"
      }
    },
    {
      "Population": "patients with advanced stage of HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "doxorubicin",
      "Countries": [
        "IT"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced stage of HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "doxorubicin"
      }
    },
    {
      "Population": "patients with advanced HCC, not eligible for any loco-regional treatment (either at diagnosis or after failure of any previous treatments), with good liver function (Child-Pugh)",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "IT"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced HCC, not eligible for any loco-regional treatment (either at diagnosis or after failure of any previous treatments), with good liver function (Child-Pugh)",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "patients with (locally) advanced hepatocellular carcinoma, where no resection, ablation or TACE is possible",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "Transarterial radioembolization (TARE)",
      "Countries": [
        "NL"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with (locally) advanced hepatocellular carcinoma, where no resection, ablation or TACE is possible",
        "intervention": "Medicine X (under assessment)",
        "comparator": "Transarterial radioembolization (TARE)"
      }
    },
    {
      "Population": "patients with (locally) advanced hepatocellular carcinoma, where no resection, ablation or TACE is possible",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "NL"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with (locally) advanced hepatocellular carcinoma, where no resection, ablation or TACE is possible",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "patients with (locally) advanced hepatocellular carcinoma, where no resection, ablation or TACE is possible",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "atezolizumab plus bevacizumab",
      "Countries": [
        "NL"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with (locally) advanced hepatocellular carcinoma, where no resection, ablation or TACE is possible",
        "intervention": "Medicine X (under assessment)",
        "comparator": "atezolizumab plus bevacizumab"
      }
    },
    {
      "Population": "patients with (locally) advanced hepatocellular carcinoma, where no resection, ablation or TACE is possible",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "lenvatinib",
      "Countries": [
        "NL"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with (locally) advanced hepatocellular carcinoma, where no resection, ablation or TACE is possible",
        "intervention": "Medicine X (under assessment)",
        "comparator": "lenvatinib"
      }
    },
    {
      "Population": "patients with non-surgical hepatocellular carcinoma in good general condition and with good liver function (Child and Pugha Class A)",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "combination of bevacizumab and atezolizumab",
      "Countries": [
        "PO"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with non-surgical hepatocellular carcinoma in good general condition and with good liver function (Child and Pugha Class A)",
        "intervention": "Medicine X (under assessment)",
        "comparator": "combination of bevacizumab and atezolizumab"
      }
    },
    {
      "Population": "patients previously treated with Sorafenib with AFP ≥ 400 ng/ ml",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "ramucyrumab",
      "Countries": [
        "PO"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients previously treated with Sorafenib with AFP ≥ 400 ng/ ml",
        "intervention": "Medicine X (under assessment)",
        "comparator": "ramucyrumab"
      }
    },
    {
      "Population": "patients who have previously received bevacizumab with atezolizumab",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "PO"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients who have previously received bevacizumab with atezolizumab",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "patients who have previously received bevacizumab with atezolizumab",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "leninivat",
      "Countries": [
        "PO"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients who have previously received bevacizumab with atezolizumab",
        "intervention": "Medicine X (under assessment)",
        "comparator": "leninivat"
      }
    },
    {
      "Population": "patients who have previously received bevacizumab with atezolizumab",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "cabozantinib",
      "Countries": [
        "PO"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients who have previously received bevacizumab with atezolizumab",
        "intervention": "Medicine X (under assessment)",
        "comparator": "cabozantinib"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma with good functional status (WHO PS 0-1) with good liver function (Child Pugh A)",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "atezolizumab and bevacizumab",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma with good functional status (WHO PS 0-1) with good liver function (Child Pugh A)",
        "intervention": "Medicine X (under assessment)",
        "comparator": "atezolizumab and bevacizumab"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma with good functional status (WHO PS 0-1) with good liver function (Child Pugh A) when combination therapy is inappropriate",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "tremelimumab-durvalumab combination",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma with good functional status (WHO PS 0-1) with good liver function (Child Pugh A) when combination therapy is inappropriate",
        "intervention": "Medicine X (under assessment)",
        "comparator": "tremelimumab-durvalumab combination"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma with good functional status (WHO PS 0-1) with good liver function (Child Pugh A) who cannot be offered atezolizumab, bevacizumab or tremelimumab",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "lenvatinib",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma with good functional status (WHO PS 0-1) with good liver function (Child Pugh A) who cannot be offered atezolizumab, bevacizumab or tremelimumab",
        "intervention": "Medicine X (under assessment)",
        "comparator": "lenvatinib"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma with good functional status (WHO PS 0-1) with good liver function (Child Pugh A) who cannot be offered atezolizumab, bevacizumab or tremelimumab",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma with good functional status (WHO PS 0-1) with good liver function (Child Pugh A) who cannot be offered atezolizumab, bevacizumab or tremelimumab",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma following progression on first line treatment with tyrosine kinase inhibitor",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "regorafenib",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma following progression on first line treatment with tyrosine kinase inhibitor",
        "intervention": "Medicine X (under assessment)",
        "comparator": "regorafenib"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma following progression on first line treatment with tyrosine kinase inhibitor",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "cabozantinib",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma following progression on first line treatment with tyrosine kinase inhibitor",
        "intervention": "Medicine X (under assessment)",
        "comparator": "cabozantinib"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma following progression on first line treatment with tyrosine kinase inhibitor",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "ramucirumab",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma following progression on first line treatment with tyrosine kinase inhibitor",
        "intervention": "Medicine X (under assessment)",
        "comparator": "ramucirumab"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma after first line treatment with atezolizumab-bevacizumab",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "lenvatinib",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma after first line treatment with atezolizumab-bevacizumab",
        "intervention": "Medicine X (under assessment)",
        "comparator": "lenvatinib"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma after first line treatment with atezolizumab-bevacizumab",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma after first line treatment with atezolizumab-bevacizumab",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma after first line treatment with atezolizumab-bevacizumab",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "regorafenib",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma after first line treatment with atezolizumab-bevacizumab",
        "intervention": "Medicine X (under assessment)",
        "comparator": "regorafenib"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma after first line treatment with atezolizumab-bevacizumab",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "cabozantinib",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma after first line treatment with atezolizumab-bevacizumab",
        "intervention": "Medicine X (under assessment)",
        "comparator": "cabozantinib"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma after first line treatment with atezolizumab-bevacizumab",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "ramucirumab",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma after first line treatment with atezolizumab-bevacizumab",
        "intervention": "Medicine X (under assessment)",
        "comparator": "ramucirumab"
      }
    }
  ]
}